Literature DB >> 19460201

Selective (intra-arterial), rapid infusion chemo-radiotherapy to preserve the larynx in advanced laryngeal carcinoma: preliminary results.

T Nakashima1, T Mihoki, T Ono, H Umeno, N Tanaka.   

Abstract

OBJECTIVES: We had previously treated patients with advanced stage laryngeal cancer by laryngectomy with or without post-operative radiotherapy. In order to improve such patients' quality of life, we sought to preserve the larynx by selective (intra-arterial), rapid infusion chemotherapy combined with radiotherapy.
METHODS: Chemotherapy was administered intra-arterially in the angiography suite via transfemoral catheterisation of the superior thyroid artery. Patients received up to four once-weekly infusions of cisplatin (75 mg/patient) with simultaneous intravenous administration of sodium thiosulphate, a neutralising agent. Patients also received external radiation simultaneously at a dose of 1.8 or 2.0 Gy per fraction, once daily for five days a week for 7 weeks.
RESULTS: Intra-arterial infusion chemo-radiotherapy was performed in eight patients with advanced laryngeal carcinoma (four glottic, three supraglottic and one subglottic type carcinoma). A complete response was achieved at the primary site and at lymph node metastases in all eight patients. Overall toxic side effects were modest. No catheter-related thrombo-embolic complications were observed during any of the chemotherapy sessions.
CONCLUSIONS: Selective (intra-arterial), rapid infusion chemo-radiotherapy may enable laryngeal preservation in patients with advanced laryngeal carcinoma.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19460201     DOI: 10.1017/S0022215109005052

Source DB:  PubMed          Journal:  J Laryngol Otol Suppl        ISSN: 0144-2945


  1 in total

1.  Combined modality therapy for laryngeal cancer with superselective intra-arterial cisplatin infusion and concomitant radiotherapy.

Authors:  Shigenari Taki; Akihiro Homma; Fumiyuki Suzuki; Nobuhiko Oridate; Hiromitsu Hatakeyama; Takatsugu Mizumachi; Satoshi Kano; Jun Furusawa; Tomohiro Sakashita; Naoya Inamura; Daisuke Yoshida; Rikiya Onimaru; Hiroki Shirato; Satoshi Fukuda
Journal:  Int J Clin Oncol       Date:  2011-10-01       Impact factor: 3.402

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.